Skip to content

Geron GERN Price / sales

Price / sales at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
2.6×-0.1×
Incyte logo
IncyteINCY
3.5×+0.8×
Immunome logo
ImmunomeIMNM
616.2×+563×
Syndax Pharmaceuticals logo
Syndax PharmaceuticalsSNDX
9.5×-14.7×
Arcus Biosciences logo
Arcus BiosciencesRCUS
11.5×+5.6×
Tango Therapeutics logo
Tango TherapeuticsTNGX
52.4×+48.8×

Other financials

Income statement

See full
Revenue$51.8M+30.9%
Operating income$158.0K+101%
Net income-$3.6M+81.6%
EPS (diluted)-$0.01+66.7%

Balance sheet

See full
Cash & equivalents$48.7M-12.2%
Total debt$134.0M+10.0%
Total equity$229.1M-14.6%
Total assets$534.1M-5.0%

Cash flow

See full
Operating cash flow-$62.9M-31.1%
CapEx$206.0K+2.0%
Free cash flow-$43.8M-6.8%

Valuation

See full
Market cap$888.51M-7.6%
Enterprise value$973.78M-5.3%

Profitability

See full
Operating margin-705.5%-351pp
Net margin-682.5%-339pp
FCF margin-734.4%-365pp

Returns & leverage

See full
Return on equity-27.1%-7.8pp
Debt / equity0.6×+0.1×
Current ratio6.8×-1.1×

Where this comes from

Calculated from Geron’s reported figures.

Based on the most recent quarter.

The official record: Geron’s 10-Q, filed November 7, 2024, on SEC EDGAR. View the filing →

Ask your AI about Geron's price / sales.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Geron's price / sales?
Geron (GERN) reported price / sales of 92.8× in Q3 2024.
How has Geron's price / sales changed year-over-year?
Geron's price / sales decreased by 97.3% year-over-year, from 3,500.1× to 92.8×.
What is the long-term trend for Geron's price / sales?
Over 3 years (2020 to 2023), Geron's price / sales has grown at a 33.7% compound annual growth rate (CAGR), from 2,023.3× to 4,834.9×.
What does price / sales mean?
Market capitalization at the quarter end divided by trailing-twelve-month revenue. The price the market pays for each dollar of sales.